Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

1-Year Data Analysis from a Cancer Center Molecular Tumor Board Dedicated to Clonal Hematopoiesis

Blood (2023) 142 (Supplement 1): 1322.

https://doi.org/10.1182/blood-2023-186721

Published: 2023

Journal Articles

Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

Blood (2023) 142 (Supplement 1): 1471.

https://doi.org/10.1182/blood-2023-174446

Published: 2023

Journal Articles

Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 537–538.

https://doi.org/10.1182/blood-2022-165464

Published: 2022

Journal Articles

SRSF2-P95Hdelays Myelofibrosis Development through Altered JAK/STAT Signaling in JAK2-V617F Megakaryocytes

Blood (2021) 138 (Supplement 1): 2544.

https://doi.org/10.1182/blood-2021-149757

Published: 2021

Journal Articles

Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia

Nicolas Duployez, Christophe Willekens, Isabelle Plo, Alice Marceau-Renaut, Stéphane de Botton, Laurène Fenwarth, Thomas Boyer, Guillemette Huet, Olivier Nibourel, Christian Rose, Brigitte Nelken, Bruno Quesnel, Claude Preudhomme

Blood (2019) 134 (26): 2414–2416.

https://doi.org/10.1182/blood.2019003206

Published: 2019

Includes: Supplemental data

Journal Articles

Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Sabine Khalife-Hachem, Khalil Saleh, MD, Florence Pasquier, MD PhD, Anthony Tarabay, Cyril Quivoron, Sophie Cotteret, Christophe Willekens, MD, Veronique Saada, Ines-Maria Vaz-Luis, Suzette Delaloge, Alexandra Leary, Hana Raslova, PhD, Filippo Rosselli, Olivier Caron, Iléana Antony-Debre, PhD, Eric Solary, MD PhD, Stephane de Botton, MD PhD, Christophe Marzac, MD, Jean-Baptiste Micol, MD

Blood (2019) 134 (Supplement_1): 3722.

https://doi.org/10.1182/blood-2019-126872

Published: 2019

Journal Articles

ATG2B/Gskip in De Novo Acute Myeloid Leukemia (AML): High Prevalence of Germline Predisposition in French West Indies and Potential Role of Overexpression in Acquired AML

Blood (2018) 132 (Supplement 1): 1482.

https://doi.org/10.1182/blood-2018-99-110366

Published: 2018

Journal Articles

Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 724.

https://doi.org/10.1182/blood.V130.Suppl_1.724.724

Published: 2017

Journal Articles

Dose-Adjusted Rituximab Mini-CYVE (CYtarabine bolus, VEpeside and dexamethasone) for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Not Eligible for High Dose Therapy

Yolla EL Dakdouki, Jean-Marie Michot, MD, Julien Lazarovici, MD, Khalil Saleh, MD, David Ghez, MD PhD, Claude Chahine, MD, Loic Verlingue, Christophe Willekens, MD, Veronique Vergé, Christophe Ferme, MD, Alina Danu, MD, Vincent Ribrag, MD

Blood (2017) 130 (Supplement 1): 2847.

https://doi.org/10.1182/blood.V130.Suppl_1.2847.2847

Published: 2017

Journal Articles

Efficacy of 5-Azacitidine on IDH1/2 Acute Myeloid Leukemia/Myelodysplastic Syndromes and Correlation with 2-Hydroxyglutarate Production

Christophe Willekens, MD, Veronique Saada, Sophie Broutin, Julia Delahousse, Aline Renneville, MDPhD, Cynthia Petrovanu, Christophe Marzac, Jean-Baptiste Micol, MD PhD, Éric Solary, MD PhD, Florence Pasquier, MD PhD, Julien Lazarovici, MD, Vincent Ribrag, Claude Preudhomme, PharmD, PhD, Cyril Quivoron, Virginie Penard-Lacronique, PhD, Angelo Paci, Stephane de Botton, MD PhD

Blood (2017) 130 (Supplement 1): 1313.

https://doi.org/10.1182/blood.V130.Suppl_1.1313.1313

Published: 2017

Journal Articles

The Impact of Risk-Adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplantation

Riwa Sakr, MD, Sylvain Pilorge, MD, Stephane De Botton, Claude Chahine, MD, Tereza Coman, MD PhD, Marcel Adler, MD, Jean-Baptiste Micol, MD PhD, Florence Pasquier, MD PhD, Christophe Willekens, MD, Alina Danu, MD, Julien Lazarovici, MD, David Ghez, MD PhD, Eric Solary, MD, Vincent Ribbag, Jean-Henri Bourhis, Cristina Castilla-LLorente, MD PhD

Blood (2017) 130 (Supplement 1): 5544.

https://doi.org/10.1182/blood.V130.Suppl_1.5544.5544

Published: 2017

Journal Articles

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Blood (2017) 130 (6): 722–731.

https://doi.org/10.1182/blood-2017-04-779405

Published: 2017

Includes: Supplemental data

Journal Articles

Repetitive Low-Dose Radiation Therapies As an Alternative Option for Indolent Non-Hodgkin Lymphoma

Khalil Saleh, MD, Jean-Marie Michot, MD, Alina Danu, MD, Julien Lazarovici, MD, Nadine Khalifé-Saleh, MD, David Ghez, PhD MD, Claude Chahine, MD, Yolla Dakdouki, MD, Jonathan Fahri, Resident, Christophe Willekens, MD, Angela Boros, MD, Julia Arfi-Rouche, MD, Pierre Maroun, MD, Eric Deutsch, PhD MD, Vincent Ribrag, MD, Renaud Mazeron, MD

Blood (2016) 128 (22): 1784.

https://doi.org/10.1182/blood.V128.22.1784.1784

Published: 2016

Journal Articles

Synthetic Lethal Interactions of MDS-Associated Spliceosomal Gene Mutations Identifies the Basis for Their Mutual Exclusivity

Stanley Chun-Wei Lee, PhD, Khrystyna Dilai, Esther A. Obeng, MDPhD, Eunhee Kim, PhD, Jean-Baptiste Micol, MD PhD, Akihide Yoshimi, MD PhD, Christophe Willekens, MD, Daichi Inoue, Véronique Saada, PharmD, Hana Cho, Young Rock Chung, MS, James Palacino, PhD, Michael Seiler, PhD, Silvia Buonamici, PhD, Peter Smith, Benjamin L. Ebert, MD PhD, Robert Bradley, PhD, Omar Abdel-Wahab, MD

Blood (2016) 128 (22): 961.

https://doi.org/10.1182/blood.V128.22.961.961

Published: 2016

Journal Articles

Survival Improvement in Therapy Related Myeloid Neosplasm ? a Single Center Analysis of 428 Patients

Khalil Saleh, MD, Christophe Willekens, MD, Jean Edouard Martin, Myriam Kossai, Nadine Khalifé-Saleh, MD, Véronique Saada, PharmD, Nathalie Auger, Alina Danu, MD, Julien Lazarovici, MD, Alexandra Leary, Suzette Delaloge, Jean Henri Bourhis, MD PhD, Éric Solary, MD PhD, Serge Koscielny, Stephane de Botton, Jean-Baptiste Micol, MD PhD

Blood (2016) 128 (22): 4006.

https://doi.org/10.1182/blood.V128.22.4006.4006

Published: 2016

Journal Articles

Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study

Tim Somervaille, MD PhD, Olga Salamero, MD, Pau Montesinos, MD PhD, Christophe Willekens, MD, Jose Antonio Perez Simon, MD, Arnaud Pigneux, MD, Christian Recher, MD PhD, Rakesh Popat, Cesar Molinero, MD PhD, Christina Mascaro, PhD, Tamara Maes, PhD, Francesc Bosch, MD PhD

Blood (2016) 128 (22): 4060.

https://doi.org/10.1182/blood.V128.22.4060.4060

Published: 2016

Journal Articles

A Series of 116 Therapy-Related Myeloid Neoplasms (t-MN) Patients from 2 French Comprehensive Cancer Centers

Hind Bennani, PharmD, Véronique Saada, PharmD, Christophe Willekens, MD, Jacques Vargaftig, MD

Blood (2015) 126 (23): 1322.

https://doi.org/10.1182/blood.V126.23.1322.1322

Published: 2015

Journal Articles

Serum 2-Hydroxyglutarate Allows Early Prediction of Response during Induction Chemotherapy in Acute Myeloid Leukemia with IDH Mutation

Christophe Willekens, MD, Angelo Paci, Serge Koscielny, Alice Marceau, Jean-Baptiste Micol, MD, Sophie Broutin, Cyril Quivoron, Véronique Saada, Vianney Poinsignon, Franck Griscelli, Vincent Ribrag, MD, Cristina Castilla-Llorente, Claude Preudhomme, Virginie Lacronique-Penard, Stéphane De Botton

Blood (2015) 126 (23): 3833.

https://doi.org/10.1182/blood.V126.23.3833.3833

Published: 2015

Journal Articles

Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma

Christophe Willekens, MD, Jean-Baptiste Micol, MD, Vianney Poinsignon, Cyril Quivoron, Véronique Saada, Sophie Broutin, Marie Terroir-Cassou-Mounat, David Ghez, Jean-Henri Bourhis, MD PhD, Jacques Bosq, MD, Vincent Ribrag, MD, Angelo Paci, Virginie Lacronique-Penard, Stéphane De Botton

Blood (2015) 126 (23): 3835.

https://doi.org/10.1182/blood.V126.23.3835.3835

Published: 2015

Journal Articles

Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

Blood (2015) 125 (23): 3618–3626.

https://doi.org/10.1182/blood-2015-01-620781

Published: 2015

Includes: Supplemental data

NARROW

1-Year Data Analysis from a Cancer Center Molecular Tumor Board Dedicated to Clonal Hematopoiesis

Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia

SRSF2-P95Hdelays Myelofibrosis Development through Altered JAK/STAT Signaling in JAK2-V617F Megakaryocytes

Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia

Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

ATG2B/Gskip in De Novo Acute Myeloid Leukemia (AML): High Prevalence of Germline Predisposition in French West Indies and Potential Role of Overexpression in Acquired AML

Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia

Dose-Adjusted Rituximab Mini-CYVE (CYtarabine bolus, VEpeside and dexamethasone) for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Not Eligible for High Dose Therapy

Efficacy of 5-Azacitidine on IDH1/2 Acute Myeloid Leukemia/Myelodysplastic Syndromes and Correlation with 2-Hydroxyglutarate Production

The Impact of Risk-Adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplantation

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Repetitive Low-Dose Radiation Therapies As an Alternative Option for Indolent Non-Hodgkin Lymphoma

Synthetic Lethal Interactions of MDS-Associated Spliceosomal Gene Mutations Identifies the Basis for Their Mutual Exclusivity

Survival Improvement in Therapy Related Myeloid Neosplasm ? a Single Center Analysis of 428 Patients

Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study

A Series of 116 Therapy-Related Myeloid Neoplasms (t-MN) Patients from 2 French Comprehensive Cancer Centers

Serum 2-Hydroxyglutarate Allows Early Prediction of Response during Induction Chemotherapy in Acute Myeloid Leukemia with IDH Mutation

Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma

Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only